Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | ACACA | Q13085 | 1/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.35 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | PLA2G2C | Q5R387 | 4/20 | 0.33 |
| ▸ | ACLY | P53396 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2988405 | 0.84 | CYP4F2 (0.36) | ACACBACACACYP4F2CYP4A11ACLY | |
| SCHEMBL2988784 | 0.77 | CYP4F2 (0.33) | ACACBACACACYP4F2CYP4A11ACLY | |
| SCHEMBL23613258 | 0.76 | CYP2D6 (0.35) | SPHK1SPHK2PLA2G2C | |
| SCHEMBL21015967 | 0.76 | SPHK1 (0.37) | SPHK1SPHK2USP2HTT | |
| SCHEMBL21016306 | 0.76 | SPHK1 (0.37) | SPHK1SPHK2USP2HTT | |
| SCHEMBL23613454 | 0.75 | PLA2G2C (0.30) | PLA2G2C | |
| SCHEMBL23872743 | 0.74 | CNR1 (0.36) | PLA2G2C | |
| SCHEMBL21015899 | 0.74 | HRH3 (0.38) | SPHK1SPHK2USP2HTT | |
| SCHEMBL10119365 | 0.73 | SPHK1 (0.44) | SPHK1SPHK2PLA2G2CUSP2HTT | |
| SCHEMBL31086433 | 0.73 | SPHK1 (0.44) | SPHK1SPHK2PLA2G2CUSP2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200361939-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED. | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361939-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | SERPINA2, SERPINC1, SERPINA3 | ACACB 969/4885ACACA 266/4885SPHK1 3873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.